- Number of Upgrades
- 21 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.7
- Ratings Breakdown
- 14 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $94.00 (6.3% Upside)
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Recent Analyst Ratings
Recent Recommendations for Gilead Sciences:
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Royal Bank of Canada from $81.00 to $84.00. They now have a "sector perform" rating on the stock. (11/18/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $110.00 price target on the stock. (11/15/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $125.00 price target on the stock. (11/14/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating. (11/13/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a "hold" rating on the stock. (11/8/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. (11/8/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Royal Bank of Canada from $75.00 to $81.00. They now have a "sector perform" rating on the stock. (11/7/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $105.00. They now have an "overweight" rating on the stock. (11/7/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $105.00. They now have an "overweight" rating on the stock. (11/7/2024)
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Piper Sandler from $95.00 to $105.00. They now have an "overweight" rating on the stock. (11/7/2024)
